<|endoftext|> him they were done doing business with him.
The legislation that was signed by New York Gov. Andrew Cuomo, known as the Reproductive Health Act, not only legalizes late-term abortions but allows non-doctors to perform abortions, according to Syracuse.com.
Additionally, the legislation was passed and signed into law on the anniversary of Roe v. Wade, the 1973 Supreme Court decision that created a constitutional right to an abortion.
This fact wasn’t lost on Speed.
RELATED: Federal Government Files Suit After Kroger Allegedly Fires 2 Women Who Refused To Wear LGBT-Linked Symbol
“It was definitely intentional,” he said. “Cuomo has not been shy about slapping conservatives around New York state.
“He said at one point, I think a couple of years ago, that people like us don’t even belong in this state,” Speed added.
Speed said that what is happening in New York in regards to the legislation is what could happen across the United States if Roe v. Wade is overturned.
“I think what you’ll see is a lot of states step up and make abortion legal,” he said.
“When it comes to this abortion fight,” Speed added, “you just have to go and be faithful and do what you know is right.”
“My belief is that it takes a heart change in order to change this issue on the larger scale. The job in front of us as pro-lifers is to preach the gospel,” he said.
“We have the evidence on our side, but what it really takes is a heart change.”
We are committed to truth and accuracy in all of our journalism. Read our editorial standards.<|endoftext|>Clinical significance of the reversed mitral annular motion velocity wave at the beginning of the mitral valve closure.
Pulsed tissue Doppler imaging is increasingly used to record mitral annular motion (MAM) velocity pattern. A reversed MAM velocity wave (Cm) is commonly seen at the beginning of the mitral valve closure in timing, whereas the underlying mechanism and clinical significance have not been studied. Conventional, pulsed Doppler, pulsed tissue Doppler, and two-dimensional strain echocardiography were performed in 100 consecutive patients with cardiovascular risk factors. There were no correlations between the peak Cm and the ratio of peak early diastolic transmitral flow velocity to peak early diastolic MAM velocity (E/Em) and Tei index. The peak Cm correlated with left ventricular (LV) ejection fraction, left atrial volume index (LAVI) and left atrial ejection fraction, isovolumic relaxation time, peak LV systolic strains and strain rates during atrial systole in the longitudinal and circumferential directions, and peak LV systolic strain rates in the longitudinal, circumferential, and radial directions. Multivariate linear regression analysis revealed that LAVI is a independent predictor related to peak Cm. The Cm is regulated by mitral annular motion velocity toward the LA due to closing of the mitral valve, and may be used as a predictive tool for determining the "disease history" of chronic LV diastolic dysfunction in patients with no marked elevation in the LV filling pressure.<|endoftext|>Background {#Sec1}
==========
The slowly growing, spore-forming, Gram-positive bacterium *Actinoplanes* sp. SE50/110 (ATCC 31044), is a natural derivative of SE50. It was isolated from a soil sample during a screening program by the Bayer AG in 1970 as natural producer of an α-glucosidase inhibitor \[[@CR1], [@CR2]\]. The discovered inhibitor, subsequently known as acarbose, consists of the pseudo-tetrasaccharide acarviosyl-1,2-maltose, which leads to the irreversible inhibition of α-glucosidases, like the one from the human intestine \[[@CR3]\]. Physiologically, the inhibition of intestinal glucosidases leads to a retarded release of monosaccharides, especially of glucose, and therefore reduced resorption and decreased postprandial blood and serum sugar levels. These are assumed to be crucial for the cardiovascular disease mortality in the context of the complex pathology of diabetes \[[@CR4], [@CR5]\]. Since the early 1990s acarbose is used in the medical treatment of type II diabetes mellitus and marketed under the name Glucobay^®^ by the Bayer AG \[[@CR4], [@CR6]\].
The biosynthetic pathway of aminoglycosides---like acarbose---is based on monofunctional enzymes catalyzing single steps \[[@CR3]\]. Their corresponding biosynthesis gene cluster was first identified in 1999 by Stratmann et al. and subsequently sequenced (GenBank: Y18523.4) \[[@CR7], [@CR8]\]. The cluster contains 22 genes (Fig. [1](#Fig1){ref-type="fig"}), including genes predicted to encode for proteins of the biosynthetic pathway (AcbCMOLNUJRSIVBA), extracellular starch degradation (